US: 800.298.5699
Int'l: +1.240.747.3093
 
Matching geography
Reports matching your search in:
 
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!
 

Drug Discovery: market research reports

RSS Feeds

Drug Discovery market research reports and industry analysis

1  2  3  4    6    8  9  10  
Hematological Cancers Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 737 hematological cancer drugs in 1563 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 228 drugs. Hematological Cancers ...  |  read more...
$7,497.50
HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... (O(2)) and nutrient availability. The hypoxia-inducible factors (HIFs) are a common link between adaptation to low O(2), changes in cancer metabolism, and malignant progression. This report focusses around the cancer drugs targeting the hypoxia-inducible factor ...  |  read more...
$5,622.50
ID Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... other family members inhibiting their DNA binding capacity. This family of proteins is comprised of IDs 1, 2, 3 and 4. There are today 94 companies plus partners developing 96 ID pathway targeting drugs in ...  |  read more...
$1,872.50
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... the MAPK signaling module and activate NFkB, they are synergistic and complement each other's activity. There are today 85 companies plus partners developing 84 IL-1 pathway targeting drugs in 309 developmental projects in cancer. In ...  |  read more...
$3,747.50
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... drugs in 936 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 102 drugs. Il-3 Signaling Pathway In Oncology ...  |  read more...
$5,622.50
IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 697 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 78 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline ...  |  read more...
$5,622.50
IL-6 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... drugs in 1174 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 152 drugs. Il-6 Signaling Pathway In Oncology ...  |  read more...
$5,622.50
IL-7 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 26 drugs. Il-7 Signaling Pathway In Oncology Drug Pipeline Update lists ...  |  read more...
$1,872.50
IL-9 Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 27 drugs. Il-9 Signaling Pathway In Oncology Drug Pipeline Update ...  |  read more...
$3,747.50
Immunotherapy in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... of antibodies, vaccines, and immunostimulators in oncology drug development into one source. There are today 597 companies plus partners developing 1058 cancer immunotherapy drugs in 2719 developmental projects in cancer. In addition, there are 19 ...  |  read more...
$9,187.50
Interfering With the ECM-Receptor Interaction for the Treatment of Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... tissue and organ morphogenesis and in the maintenance of cell and tissue structure and function. There are today 47 companies plus partners developing 34 targeting ECM-receptor interaction drugs in 101 developmental projects in cancer. In ...  |  read more...
$1,872.50
Kit Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... with several human malignancies include leukemias, gastrointestinal stromal tumors and mastocytomas. There are today 178 companies plus partners developing 289 Kit receptor pathway targeting drugs in 1178 developmental projects in cancer. In addition, there are ...  |  read more...
$5,622.50
Leptin Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... partners developing 374 Leptin pathway targeting drugs in 1339 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 179 ...  |  read more...
$5,622.50
Liver Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... drugs over the last years amount to another 54 drugs. Liver Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 189 ...  |  read more...
$3,747.50
Mitochondrial Drugs in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... the differences in mitochondrial functions between tumor and normal cells can be the key to design selective anti-cancer therapies. Compounds that directly affect mitochondrial functions are considered to present a promising alternative approach to eradicate ...  |  read more...
$5,622.50
Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... In addition, there is 1 suspended drug and the accumulated number of ceased drugs over the last years amount to another 135 drugs. Modulators Of The Actin Cytoskeleton For The Treatment Of Cancer Drug Pipeline ...  |  read more...
$5,622.50
Neuroendocrine Tumors Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... last years amount to another 16 drugs. Neuroendocrine Tumors Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 81 different targets. All ...  |  read more...
$3,747.50
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... are today 231 companies plus partners developing 281 nucleic acid therapy drugs in 613 developmental projects in cancer. In addition, there are 8 suspended drugs and the accumulated number of ceased drugs over the last ...  |  read more...
$5,622.50
Ovarian Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... an important secondary indication for existing and pipeline drugs. There are today 242 companies plus partners developing 335 drugs targeting ovarian cancer in development. In addition, there are 8 suspended drugs and the accumulated number ...  |  read more...
$5,622.50
p53 Signaling Pathway in Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... transcriptional activator of p53-regulated genes. This results in three major outputs; cell cycle arrest, cellular senescence or apoptosis. Other p53-regulated gene functions communicate with adjacent cells, repair the damaged DNA or set up positive and ...  |  read more...
$3,747.50
Pancreatic Cancer Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... drugs over the last years amount to another 114 drugs. Pancreatic Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 277 ...  |  read more...
$5,622.50
Protein Kinase Inhibitors in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... three successful drugs are just the top of an emerging line of therapy. Given the fact that they all target tyrosine kinases and that kinase mutations can cause patients to become resistant to these drugs, ...  |  read more...
$5,622.50
Radiation Therapy in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... 715 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 140 drugs. Radiation Therapy In Oncology Drug Pipeline Update ...  |  read more...
$5,622.50
RANKL Signaling Pathway in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... and plays a major role in the regulation of osteoclast function. Binding of RANKL to RANK leads to the activation of signaling modules such as NF-kappa B, mitogen activated protein kinases (MAPK's), protein kinase C ...  |  read more...
$5,622.50
RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
... molecules or protein-based therapies. There are today 56 companies plus partners developing 96 RNA (miRNA, RNAi & siRNA) drugs in 129 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the ...  |  read more...
$3,747.50
1  2  3  4    6    8  9  10  
 
Our Clients